Molnupiravir: A versatile prodrug against SARS-CoV-2 variants
The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …
Novel receptor, mutation, vaccine, and establishment of coping mode for SARS-CoV-2: current status and future
Z Zeng, X Geng, X Wen, Y Chen, Y Zhu… - Frontiers in …, 2023 - frontiersin.org
Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and
its resultant pneumonia in December 2019, the cumulative number of infected people …
its resultant pneumonia in December 2019, the cumulative number of infected people …
Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the …
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) arose in December 2019
in China rapidly evolving to the Coronavirus Disease 2019 (COVID-19) pandemic. Since …
in China rapidly evolving to the Coronavirus Disease 2019 (COVID-19) pandemic. Since …
Antiviral activity of molnupiravir precursor NHC against SARS-CoV-2 Variants of Concern (VOCs) and its therapeutic window in a human lung cell model
Synopsis Background The UK Medicines and Regulatory Healthcare Agency (MHRA) have
recently licensed the anti-viral drug, molnupiravir, for use in patients with mild-moderate …
recently licensed the anti-viral drug, molnupiravir, for use in patients with mild-moderate …
Medication safety in chronic kidney disease
S Singh - Current Opinion in Nephrology and Hypertension, 2023 - journals.lww.com
Medication safety in chronic kidney disease : Current Opinion in Nephrology and Hypertension
Medication safety in chronic kidney disease : Current Opinion in Nephrology and Hypertension …
Medication safety in chronic kidney disease : Current Opinion in Nephrology and Hypertension …
Emerging strategies to reduce kidney function decline and improve cardiovascular outcomes
K Ella, SD Navaneethan - Current Opinion in Nephrology and …, 2023 - journals.lww.com
In recent years, there have been substantial developments in the treatment of kidney
disease, hypertension, and their complications. During the same period, the coronavirus …
disease, hypertension, and their complications. During the same period, the coronavirus …
[HTML][HTML] SARS-CoV-2 infection in solid organ transplant recipients: Experience with molnupiravir
MVO Len - Revista Española de Quimioterapia, 2023 - ncbi.nlm.nih.gov
Solid organ transplant recipients (SOTR) constitute one of the groups at highest risk for the
development of severe COVID-19. However, evidence on the effectiveness of treatments for …
development of severe COVID-19. However, evidence on the effectiveness of treatments for …